Why the study?
Clinical trial limitations and real-world population makeup require a balanced view of DMT benefits and risks in progressive multiple sclerosis, given patients are older with more comorbidities.
This review summarizes the efficacy and risks of disease modifying treatments for progressive multiple sclerosis in the UK to guide clinical decision making.
Answers are grounded in this paper and cite their sources.
May inform balanced DMT decisions in real-world PMS; leaves open optimal risk-benefit assessment in older, comorbid patients.
The recent availability of disease modifying treatments (DMTs) for progressive multiple sclerosis (PMS) is a welcome change, yet the limitations of clinical trial design and the real-world makeup of the PMS population necessitate a balanced view of their potential benefits and risks in a population that is on average older than the relapsing-remitting MS (RRMS) population, and more likely to have or develop comorbidities over time. Here we will review the available data for DMT efficacy and risks in PMS with a view to guiding clinician and patient in joint care decision making.
No takes yet. Share an insight, caveat, or question.
Mangion et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: